Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

来源:Reuters发布于 2026-11-03

Teva Pharmaceutical Industries expects to grow in ​2027 despite the US ‌inflation reduction act that will cap prices for its top ​branded drug Austedo to ​treat Huntington's Disease and Tardive ⁠Dyski...

相关标的:TEVA

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。